Figure 2

INSTEAD: time to first moderate or severe exacerbation over 26 weeks in patients with moderate COPD (FEV₁ 50–80% predicted) and no exacerbations for >1 year prior to study entry²⁸. SFC, salmeterol/fluticasone propionate. Reproduced with permission of the European Respiratory Society.⁶⁰